Sign In
Buy ASH
$57.58
-0.430 (-0.741%)
At Close: Jun 02, 2026
Bristol Myers Squibb Data at ASH 2025 Showcase Potential of Hematology Pipeline and Build Momentum for Next Generation Portfolio
06:59am, Monday, 01'st Dec 2025
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASH--Bristol Myers Squibb Data at ASH 2025 Showcases Potential of Hematology Pipeline and Builds Momentum for Next Generation Portfolio.
Ashland Inc. $ASH Shares Bought by Franklin Resources Inc.
04:20am, Monday, 01'st Dec 2025
Franklin Resources Inc. increased its position in Ashland Inc. (NYSE: ASH) by 3.9% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Co
Citius Oncology to Exhibit at the 67th American Society of Hematology (ASH) Annual Meeting
08:00am, Tuesday, 25'th Nov 2025
Citius Oncology's LYMPHIR™ exhibit will be located at Booth #265 LYMPHIR launch on track for Q4 2025 CRANFORD, N.J. , Nov. 25, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq:
Results from the BRUIN CLL-314 study comparing Jaypirca (pirtobrutinib) to Imbruvica (ibrutinib) – the first-ever head-to-head Phase 3 study versus a covalent BTK inhibitor to include treatment-naï
SEATTLE, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune syst
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that new data across multiple hematologic malignancies will be pre
BeOne Medicines Showcases Leadership in B-cell Malignancies at ASH 2025
06:00am, Thursday, 20'th Nov 2025
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, advances its vision to become the world's leading oncology
Ashland board authorizes quarterly dividend
05:01pm, Wednesday, 19'th Nov 2025
WILMINGTON, Del., Nov. 19, 2025 (GLOBE NEWSWIRE) -- The board of directors of Ashland Inc. (NYSE: ASH) has declared a quarterly cash dividend of $0.415 cents per share on the company's common stock. T
Oral presentation of Lynozyfic™ (linvoseltamab-gcpt) data in newly diagnosed multiple myeloma from LINKER-MM4, the first trial to evaluate a BCMAxCD3 bispecific antibody as a monotherapy in this set
CAMBRIDGE, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company accelerating potential high-impact therapies in autoimmune d
Ashland Q4 Earnings Miss Estimates on Portfolio Actions, Revenues Down
08:16am, Thursday, 06'th Nov 2025
ASH posts higher Q4 profit but weaker adjusted earnings as sales fall across key segments amid portfolio shifts.
/PRNewswire/ -- Eilean Therapeutics LLC, a biotechnology company developing next-generation precision medicines for cancer and immune-inflammatory diseases,
Ashland Inc. (ASH) Q4 2025 Earnings Call Transcript
04:11pm, Wednesday, 05'th Nov 2025
Ashland Inc. ( ASH ) Q4 2025 Earnings Call November 5, 2025 10:00 AM EST Company Participants Sandy Klugman Guillermo Novo - Chairman & CEO William Whitaker - Senior VP, CFO & Director of Investor Rel
Contrasting Ashland (NYSE:ASH) and PPG Industries (NYSE:PPG)
02:30am, Wednesday, 05'th Nov 2025
Ashland (NYSE: ASH - Get Free Report) and PPG Industries (NYSE: PPG - Get Free Report) are both basic materials companies, but which is the better stock? We will contrast the two companies based on th
Ashland (ASH) Reports Q4 Earnings: What Key Metrics Have to Say
08:31pm, Tuesday, 04'th Nov 2025
While the top- and bottom-line numbers for Ashland (ASH) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compar
